MajorAntiplatelet agents (low dose) / NSAIDs (analgesic dose)×Vitamin K antagonist anticoagulants
Updated · Methodology
Mechanism
Aspirin irreversibly blocks platelet cyclooxygenase and reduces aggregation. Warfarin blocks vitamin K-dependent clotting factor synthesis. Two different antithrombotic mechanisms add up. Aspirin also injures the gastric mucosa, raising bleeding risk independently of coagulation parameters.
Symptoms
Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.
Management
High doses of aspirin and other salicylates are contraindicated with warfarin (warfarin SmPC). Analgesic doses of aspirin are not recommended with warfarin and are used only when there is no alternative (aspirin 500 mg SmPC). Aspirin is added to warfarin deliberately, for specific indications: the US warfarin label (FDA) allows it with prosthetic heart valves depending on valve type and position, and for high-risk patients after myocardial infarction lists warfarin plus aspirin up to 100 mg a day. With this combination, monitor the INR carefully (aspirin 100 mg SmPC) and watch for signs of bleeding (US warfarin label). Tell the patient not to start or stop aspirin or other salicylates, including over-the-counter products, without the doctor's advice (US warfarin label).
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- Pharmaceutical Press: Stockley's Drug Interactions, 12th edition (2024)– Preston CL (ed.). Stockley's Drug Interactions. 12th ed. London: Pharmaceutical Press; 2024
- ESC: 2023 ESC Guidelines for the management of acute coronary syndromes (2023)– Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826
- ESC: 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the EACTS (2024)– Eur Heart J 2024;45(36):3314–3414
- FDA: Jantoven (warfarin sodium tablets) – Prescribing Information (2025)– FDA, DailyMed SPL, Upsher-Smith Laboratories, разделы 5.1, 7.1 и 7.3
- AEMPS: Ficha técnica: Warfarina (nº registro 63064), sección 4.3 (2023)– AEMPS, CIMA, nº registro 63064, revisión 01/2023, sección 4.3
- AEMPS: Ficha técnica: Ácido acetilsalicílico 500 mg (Aspirina) (nº registro 2011), sección 4.5 (2026)– AEMPS, CIMA, nº registro 2011, revisión 06/2026, sección 4.5
- AEMPS: Ficha técnica: Ácido acetilsalicílico 100 mg (Adiro) (nº registro 62825), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 62825, revisión 07/2026, secciones 4.4 y 4.5